{"news_desk": "Business", "print_page": null, "subsection_name": "DealBook", "section_name": "Business Day", "byline": {"original": "By ROBERT CYRAN", "person": [{"firstname": "Robert", "rank": 1, "lastname": "CYRAN", "organization": "", "role": "reported"}]}, "abstract": null, "type_of_material": "News", "word_count": "348", "keywords": [{"rank": "1", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "name": "subject"}, {"rank": "2", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "name": "subject"}, {"rank": "3", "value": "Ariad Pharmaceuticals Inc", "is_major": "N", "name": "organizations"}, {"rank": "4", "value": "Takeda Pharmaceutical", "is_major": "N", "name": "organizations"}], "lead_paragraph": "The Japanese pharmaceutical offers to buy Ariad Pharmaceuticals for $5.2 billion, about 75 percent above the price where the biotech\u2019s shares were trading.", "pub_date": "2017-01-09T22:20:09+0000", "document_type": "article", "source": "The New York Times", "snippet": "The Japanese pharmaceutical offers to buy Ariad Pharmaceuticals for $5.2 billion, about 75 percent above the price where the biotech\u2019s shares were trading....", "multimedia": [], "web_url": "http://www.nytimes.com/2017/01/09/business/dealbook/takedas-bid-for-cancer-drug-maker-looks-expensive.html", "slideshow_credits": null, "blog": [], "_id": "58740cab95d0e03926079c91", "headline": {"main": "Takeda\u2019s Bid for Cancer Drug Maker Looks Expensive", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}}